Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Chikungunya

Chikungunya

9 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Chikungunya

19 trials tracked for Chikungunya: 4 in phase 3 or 4 and 3 with published results. The most-cited published study has 231 citations.

19Trials tracked
4Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 4 Phase 2 8 Phase 1 3 Other / NA 4
  1. Phase 3 Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults Completed · 231 cited
  2. Phase 3 A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine) Completed · 78 cited
  3. Phase 3 Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years Completed · 78 cited
  4. Phase 3 Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults Completed
  5. Phase 2 A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine Completed
  6. Phase 2 Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) Completed
Show 13 more trials
  1. Phase 2 Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006) Completed
  2. Phase 2 Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults Completed
  3. Phase 2 Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults Completed
  4. Phase 2 Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area Completed
  5. Phase 2 Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine Completed
  6. Phase 2 Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005) Completed
  7. Phase 1 Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants Completed
  8. Phase 1 Chikungunya Virus Vaccine Trial in Healthy Adults Completed
  9. Phase 1 Phase 1 Study of SAR440894 vs Placebo Completed
  10. N/A A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components Completed
  11. N/A Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases Completed
  12. N/A Defining Skin Immunity of a Bite of Key Insect Vectors in Humans Completed
  13. N/A Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia Completed

Showing the 19 most-cited and recently-updated of 19 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Chikungunya: what the trials found

Several vaccine candidates demonstrate significant immunogenicity against Chikungunya. The VLA1553 vaccine showed a fold increase in CHIKV-specific neutralizing antibody titers compared to baseline (1.02, 1.00, 1.08, and 1.00) with specific cohorts showing much higher increases (up to 460.27 or 399.91) [1, 4]. Additionally, the VRC-CHKVLP059-00-VP vaccine was evaluated for reactogenicity; local and systemic signs were reported in various groups following administration [12, 15].

The CHIKV VLP/adjuvant platform demonstrated high seroresponse rates. Specifically, anti-CHIKV SNA seroresponse rates at Day 22 reached 87.3% 2 and 97.81% 3, with corresponding Geometric Mean Titers (GMT) of 724 2 and 1618 3. These trials also observed high seroresponse rates at other time points, such as Day 15 (82.3% 2; 96.8% 3) and Day 183 (75.5% 3).

Recent results — preliminary, needs further review

  • The SAR440894 vaccine was evaluated in a Phase 1 trial 13.
  • Targeted Indoor Residual Spraying (TIRS) was evaluated as an intervention 16.

For the clinician treating this condition

  • Multiple VLP-based and adjuvanted formulations show high seroresponse rates and significant neutralizing antibody titers against Chikungunya.
  • Clinical data for the VLA1553 vaccine confirms both immunogenicity (neutralizing antibody fold increases) and safety profiles regarding unsolicited adverse events.
  • Reactogenicity data is available for the VRC-CHKVLP059-00-VP candidate to inform expectations on local and systemic responses.

AI synthesis of 4 cited trials, updated Jun 19, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
NLRP3 inhibition and IL-1 receptor blockade attenuate musculoskeletal pathology in alphavirus infections
Infectious Disease Sys. Review
NLRP3 inhibition and IL-1 receptor blockade attenuate musculoskeletal pathology in alphavirus infections Targeting specific proteins may reduce joint damage from viral infections
This mini review synthesizes preclinical data regarding NLRP3 inflammasome activation during Chikungunya, Ross River, and Mayaro virus infec…
New research suggests that blocking certain inflammatory pathways could protect bones and joints from damage caused by Chikungunya, Mayaro, …
Frontiers Jul 17, 2026
Narrative review discusses Chikungunya virus infection without reporting specific clinical data or outcomes
Allergy & Immunology Sys. Review
Narrative review discusses Chikungunya virus infection without reporting specific clinical data or outcomes Chikungunya May Become Chronic Due to Immune System Mistake
This source is a narrative review focusing on Chikungunya virus infection.
Chikungunya can trigger a chain reaction in the immune system that leads to chronic joint pain, new research shows.
Frontiers Apr 29, 2026
Environmental and social factors influence arbovirus proliferation in changing climate conditions
Infectious Disease Cohort
Environmental and social factors influence arbovirus proliferation in changing climate conditions Rising Temperatures Push Dangerous Viruses Into New Communities
This review examines how environmental and social factors, including increasing temperatures and urbanization, affect the proliferation of a…
Warming weather pushes dangerous insect-borne viruses into new areas, making early warning systems and vaccines more critical than ever for …
Frontiers Apr 28, 2026
Observational study evaluates clinical prediction models for dengue, chikungunya, and Oropouche fever in Brazil
Infectious Disease
Observational study evaluates clinical prediction models for dengue, chikungunya, and Oropouche fever in Brazil New Tool Helps Doctors Tell Dengue, Chikungunya, and Oropouche Fever Apart
This observational study analyzed surveillance data from Espirito Santo state, Brazil, involving 465,280 observations to assess clinical pre…
A new online tool can tell apart dengue, chikungunya, and Oropouche fever using simple symptoms, helping doctors make faster, more accurate …
medRxiv Apr 26, 2026
Meta-analysis of maternal Chikungunya infection and pregnancy outcomes
Pediatrics Meta-analysis
Meta-analysis of maternal Chikungunya infection and pregnancy outcomes Chikungunya in Pregnancy: When Timing Changes Everything
This meta-analysis of 57 observational studies synthesized data on maternal Chikungunya virus infection during pregnancy.
This study reveals when during pregnancy chikungunya poses the greatest danger — and it’s later than we thought.
Apr 23, 2026
VLA1553 vaccination induces sustained neutralizing antibodies in Brazilian adolescents against chikungunya virus
Drug Pipeline RCT
VLA1553 vaccination induces sustained neutralizing antibodies in Brazilian adolescents against chikungunya virus A New Shield for Teens Against Chikungunya
This randomized, placebo-controlled phase 3 trial evaluated the single-dose VLA1553 vaccine in 754 generally healthy adolescents aged 12 to …
This vaccine gives teenagers strong protection against chikungunya fever without causing serious harm.
Apr 15, 2026
Chikungunya seroprevalence was 34.3% overall, significantly higher in urban Colombo communities compared to semi-urban areas
Infectious Disease Cohort
Chikungunya seroprevalence was 34.3% overall, significantly higher in urban Colombo communities compared to semi-urban areas A Silent Threat Reawakens: Why a Major City Was Primed for an Outbreak
This observational cohort study assessed age-stratified chikungunya-specific IgG seroprevalence among 1,196 residents in Colombo, Sri Lanka,…
After 16 years without cases, Colombo's dense urban neighborhoods left residents defenseless against a chikungunya outbreak that hit hard in…
medRxiv Apr 11, 2026
Field Notes Describe Chikungunya Virus Outbreak in Paraguay
Infectious Disease
Field Notes Describe Chikungunya Virus Outbreak in Paraguay Chikungunya outbreak hits Paraguay. What does that mean for people there?
A field report describes a chikungunya virus outbreak in Paraguay.
A chikungunya outbreak is now circulating in Paraguay, where mosquitoes carry a virus that causes intense joint pain, fever, and rash.
CDC Apr 5, 2026
Phase 3 Trial Evaluates Safety and Immunogenicity of CHIKV VLP Vaccine in Children
Drug Pipeline Phase III
Phase 3 Trial Evaluates Safety and Immunogenicity of CHIKV VLP Vaccine in Children Could a New Vaccine Protect Children from Chikungunya Virus?
A Phase 3 trial is assessing the safety and immunogenicity of the CHIKV VLP vaccine in children aged 1 to <12 years.
A new vaccine is being tested to protect children aged 1 to under 12 from painful chikungunya fever and joint pain while researchers track s…
CT.gov Mar 27, 2026

Questions about Chikungunya

Can a narrative review tell me about Chikungunya virus infection outcomes?

A narrative review explains the immune mechanisms behind Chikungunya but does not provide specific clinical outcome data like infection rates or long-term recovery statistics.

Full answer →
Is the new chikungunya vaccine safe for my young child?

A Phase 3 trial is currently testing a new chikungunya vaccine for children aged 1 to 12 years to evaluate its safety and ability to build immunity.

Full answer →
How does climate change affect chikungunya outbreaks in my area?

Climate change expands the habitats of mosquitoes that carry chikungunya, allowing outbreaks to occur in new areas and during longer seasons.

Full answer →